Rheumatoid arthritis is a chronic autoimmune condition where the immune system erroneously attacks joint synovium, causing inflammation, cartilage degradation, and bone erosion.
Rheumatoid arthritis is a chronic autoimmune condition where the immune system erroneously attacks joint synovium, causing inflammation, cartilage degradation, and bone erosion. Stem-cell investigations, primarily using placental mesenchymal stem cells, explore whether these cells can modulate the underlying immune dysregulation and reduce synovial inflammation. MSCs secrete immunosuppressive cytokines and may shift macrophage polarisation from pro-inflammatory (M1) to anti-inflammatory (M2) phenotypes. With 43 registered trials and 7 currently recruiting, the therapeutic premise differs from muscular dystrophy: rather than direct tissue regeneration, MSCs aim to suppress the aberrant T-cell and B-cell responses driving the disease. Early clinical data suggest potential for joint-specific injection or systemic administration to reduce disease activity scores and inflammation markers.
| Indicative cost · Bulgaria (EU) | €3,000–€8,000 |
|---|---|
| Global market cost range | €9,200–€23,000 (bookinghealth.com) |
| Main cell types studied | MSCs from Amniotic Membrane |
| Approval status | Investigational |
| Registered trials (ClinicalTrials.gov) | 43 · 7 recruiting now |
For the clinic's own description, see how Stem Plus describes its Rheumatoid Arthritis programme ↗.
Clinical evidence in rheumatoid arthritis shows encouraging preliminary signals. Seven recruiting trials indicate sustained clinical interest and patient demand. Published trials have documented reductions in serum inflammatory markers (IL-6, TNF-α) and improvements in Disease Activity Score (DAS28) following MSC infusion, with some patients achieving low-disease-activity remission. However, many studies are small and uncontrolled, lacking the rigorous blinding and long-term follow-up expected of modern rheumatology trials. Comparisons with established DMARDs (disease-modifying antirheumatic drugs) are sparse; MSCs may complement rather than replace conventional immunosuppression. Relapse following initial improvement occurs in a proportion of participants, particularly when conventional therapy is withdrawn.
Depending on assessment, a Rheumatoid Arthritis protocol may draw on:
Rheumatoid arthritis stem-cell treatment costs typically range €3,500–6,500 per infusion, depending on cell source, expansion scale, and delivery route. Intra-articular injection into one or few joints is less expensive than systemic administration. Placental MSCs are favoured for cost-efficiency and immunogenicity profile relative to other sources. Disease duration and number of affected joints may influence whether monotherapy or repeat infusions are proposed. European programmes in Italy, Germany, and Spain generally charge at the lower end; private boutique clinics may exceed €7,000. Some trial sites offer treatments at reduced cost to enrolled participants.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, or see the Rheumatoid Arthritis cost-by-country breakdown.
Before booking, check safety & regulation, the recovery climate, whether you may be a candidate, and which cell type fits Rheumatoid Arthritis.
Full Rheumatoid Arthritis FAQ → · Rheumatoid Arthritis cost breakdown →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Am I a candidate? · Which cell type? · Types of clinics & best countries · Cost calculator
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Medicina regenerativa certificada GMP en el corazón de la UE — desde 3.000–8.000 €, una fracción de los precios de EE. UU. o Alemania. Protocolos personalizados para pacientes de más de 50 países.
Evaluación médica gratuita